Physician profile
Uma Gopakumar
NPI 1124367255
$639.69
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $285 · 2022: $354.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $131.46 | 2021-2022 | |
| Abbvie INC. | $97.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.95 | 2021-2022 | |
| Novo Nordisk INC | $67.91 | 2021-2022 | |
| Amarin Pharma, INC. | $63.84 | 2021 | |
| Amgen INC. | $46.93 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $37.76 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.92 | 2021-2022 | |
| Pfizer INC. | $29.82 | 2021-2022 | |
| Esperion Therapeutics, INC. | $19.77 | 2021 | |
| Medtronic, INC. | $15.22 | 2021 | |
| Alfasigma USA, INC. | $14.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.86 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Gopakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.